GLAdiator is a proprietary delivery platform that uses the naturally occurring gamma-carboxyglutamic-acid (GLA) domain to detect and treat cancer through recognition of phosphatidylserine on the surface of cancer cells and their extracellular vesicles (EVs).
Cancer cells and cancer EVs express the phospholipid phosphatidylserine (PS) on their cell surface (rev. in Birge et al., 2016) and healthy cells do not. GLA domains are the component of blood coagulation factors that are responsible for targeting PS and anchoring them to the site of the injury through their interaction with PS.
GLAdiator Biosciences is advancing pre-clinical research related to GLA domain targeting of PS conducted at Bayer Healthcare in collaboration with Stanford University to develop GLAdiator™, a novel, engineered GLA-domain based targeting platform for the early diagnosis and treatment of PS expressing cancer cells and their EV’s.
Current preclinical data demonstrate that GLAdiator:
1. Differentiates between PS and non-PS expressing cells in vitro and in vivo
2. Detects and rapidly internalizes into the cytoplasm of PS expressing cells
3. Delivers small molecules into these cells
4. Detects PS earlier than Annexin V
5. Detects and binds to PS expressing EVs
The company intends to develop this platform for the early non-invasive detection of cancer (via tumor derived EVs) and its subsequent treatment through targeted delivery of GLA-based therapeutics (both small molecule and biologics).